Regeneron Pharmaceuticals Inc (REGN)vsTango Therapeutics Inc (TNGX)
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
TNGX
Tango Therapeutics Inc
$20.88
+7.19%
HEALTHCARE · Cap: $2.98B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 22891% more annual revenue ($14.34B vs $62.38M). REGN leads profitability with a 31.4% profit margin vs -162.9%. REGN earns a higher WallStSmart Score of 58/100 (C).
REGN
Buy58
out of 100
Grade: C
TNGX
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Intrinsic value data unavailable for TNGX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Trading at 8.2x book value
0.0% earnings growth
ROE of -37.2% — below average capital efficiency
Revenue declined 100.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bull Case : TNGX
TNGX has a balanced fundamental profile.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : TNGX
The primary concerns for TNGX are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
REGN profiles as a value stock while TNGX is a turnaround play — different risk/reward profiles.
TNGX carries more volatility with a beta of 1.81 — expect wider price swings.
REGN is growing revenue faster at 2.5% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (58/100 vs 20/100), backed by strong 31.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Tango Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tango Therapeutics Inc. is a clinical-stage biotechnology company pioneering the development of targeted therapies aimed at addressing significant unmet needs in cancer treatment, particularly through the innovative concept of synthetic lethality. With a diverse pipeline of promising drug candidates, Tango is well-positioned to lead advancements in precision oncology, focusing on collaborative partnerships with leading research institutions to enhance its scientific capabilities. The company's strategic vision is to transform cancer care and improve patient outcomes, positioning it as a key player in the evolution of treatment paradigms in oncology.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?